United States: Lead Compound Analysis Not Applicable To Certain Method-Of-Treatment Claims

In Short

The Situation: In a Hatch-Waxman litigation, a district court determined that the claims covering a method of using the drug everolimus to treat kidney cancers were not obvious. The court found a motivation to "pursue" everolimus, but the defendant failed to show a motivation to "select" everolimus over other treatment options.

The Result: On appeal, the Federal Circuit faulted the district court for applying the "lead compound" analysis and requiring a motivation to select everolimus over other treatment options as a prerequisite for obviousness. The Federal Circuit distinguished method-of-treatment claims from compound claims to which the lead compound analysis applies.

Looking Ahead: In Novartis, the district court found a motivation to pursue, and the Federal Circuit faulted it for additionally requiring a motivation to select and for applying the lead compound analysis to method-of-treatment claims. It remains to be seen the effect of this holding on other types of claims and in cases without a finding of motivation to pursue.

In a recent case, the Federal Circuit held that the heightened requirement of preferring the claimed invention over other known alternatives found in the lead compound analysis does not apply to method-of-treatment claims. Novartis Pharm. Corp. v. W.-Ward Pharm. Int'l Ltd., 923 F.3d 1051, 1059 (Fed. Cir. 2019). The Federal Circuit distinguished method-of-treatment claims from other types of claims to which the lead compound analysis applies under its precedent, finding that the district court erred in applying the lead compound analysis to determine whether a skilled artisan would have had a motivation to combine the prior art. But ultimately, the Federal Circuit affirmed the district court's non-obviousness determination because the district court did not clearly err in finding no reasonable expectation of success.

AFINITOR® (everolimus) is approved for treating advanced renal cell carcinoma ("RCC"). Novartis owns U.S. Patent No. 8,410,131 ("'131 patent"), which claims a method of using everolimus to treat advanced kidney cancers, including advanced RCC. In a Hatch-Waxman litigation, generic defendant West-Ward sought to invalidate the '131 patent as obvious.

As of the priority date of the '131 patent, everolimus was known to inhibit mTOR, a protein that regulates cellular processes relating to cancer. Another mTOR inhibitor, temsirolimus, had been tested in Phase I clinical trials in which a small number of RCC patients showed partial or minor responses. Two Phase II clinical trials on temsirolimus were underway, one of which was designed specifically for RCC. However, there was no clinical data on everolimus for treating any cancer, much less RCC, which was known to be difficult to treat.

After a bench trial, the district court found that a skilled artisan "would have been motivated to pursue everolimus as one of several potential treatment options" for advanced RCC. Novartis, 923 F.3d at 1057 (emphasis added). But the district court noted that there were a variety of other treatments in development at the time, beyond mTOR inhibitors. The district court found that West-Ward failed to show that a skilled artisan "would have been motivated to select everolimus." Id. at 1058 (emphasis added).

On appeal, the Federal Circuit faulted the district court for applying a heightened standard in requiring a motivation to select everolimus over other treatments. Id. at 1059. Noting that the district court found a motivation to pursue everolimus, the Federal Circuit explained that "[t]his finding should have affirmatively answered whether there would have been a motivation to combine" the prior art. Id.

The Federal Circuit distinguished the method-of-treatment claims from compound claims. Id at 1060. To those claims, a court applies the lead compound analysis to determine whether there would have been a motivation to select a prior-art compound for further modification to achieve the claimed compound. Id. (citing Otsuka Pharm. Co. v. Sandoz Inc., 678 F.3d 1280, 1291–92 (Fed. Cir. 2012); Daiichi Sankyo Co. v. Matrix Labs., Ltd., 619 F.3d 1346, 1354 (Fed. Cir. 2010); Takeda Chemical Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1357 (Fed. Cir. 2007)). As to the method-of-treatment claims at issue here, the Federal Circuit explained that "[t]he proper inquiry is whether a person of ordinary skill would have been motivated to modify the prior art disclosing use of temsirolimus to treat advanced RCC with the prior art disclosing everolimus." Id.

The district court also found that West-Ward failed to show that a skilled artisan would have reasonably expected everolimus to successfully treat advanced RCC. Id. at 1058. The Federal Circuit agreed with that finding and affirmed the district court's conclusion of non-obviousness. Id. at 1059. The Federal Circuit specifically noted that (1) the temsirolimus Phase I data had diminished weight because the Phase I studies were designed to test safety, not efficacy, in a small number of patients; (2) Phase II data on temsirolimus were not yet available; (3) more than 70% of cancer drugs failed in Phase II development; (4) everolimus and temsirolimus had different pharmacological properties; and (5) the molecular biology of advanced RCC was not well understood. Id. at 1061-62. The Federal Circuit therefore concluded that the district court did not clearly err in finding that a skilled artisan would not have had a reasonable expectation for everolimus to effectively treat advanced RCC.

Three Key Takeaways:

  1. In Novartis, the Federal Circuit distinguished the method-of-treatment claims at issue from compound claims to which the lead compound analysis applies under the court's precedent.
  2. The Federal Circuit explained that the district court's finding of motivation to pursue the claimed method of treatment is sufficient to answer the question whether there was a motivation to combine the prior art.
  3. In circumstances like this, the district court erred in applying a heightened standard to require a showing of a motivation to select the claimed method over other treatment options.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions